AMINOSYN II 3.5% M
LOE Approachingamino acids; magnesium chloride; potassium chloride; sodium chloride; sodium phosphate, dibasic, heptahydrate
NDAINJECTIONINJECTABLE
Approved
Apr 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMINOSYN II 3.5% M is a parenteral nutrition solution containing essential and non-essential amino acids, electrolytes (magnesium, potassium, sodium), and phosphate. It is administered intravenously to provide nutritional support in patients unable to consume adequate nutrition orally or enterally. The formulation supplies amino acids for protein synthesis and critical electrolytes for cellular function and metabolic homeostasis.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating potential team restructuring and focus shift toward cost management and market defense.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on AMINOSYN II 3.5% M offers limited high-growth career advancement opportunities given the mature, LOE-approaching lifecycle and commodity market dynamics. Career professionals should expect focus on operational efficiency, hospital contract management, and defensive market positioning rather than brand building or clinical innovation.
Hospital Account Manager
Worked on AMINOSYN II 3.5% M at ICU Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.